The abstract is read at the publisher; the summary is JClub's.
Four doses of dapagliflozin started the day before elective cardiac surgery reduced 7-day acute kidney injury incidence from 52% to 28% versus placebo.
- Why it matters: Acute kidney injury occurs in 2% to 50% of elective cardiac surgery patients, and no preventive medication strategy has been clearly identified.
- What they did: In a multicenter, double-blind randomized trial in the Netherlands, adults received dapagliflozin 10 mg once daily (n = 392) or placebo (n = 392) for 4 doses spanning pre-op day through postoperative day 2.
- The result: Over 7-day follow-up, dapagliflozin lowered AKI incidence (relative risk, 0.54 [95% CI, 0.45-0.65]; P < .001), supporting perioperative use to reduce AKI risk in this setting.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.